Skip to main contentSkip to navigationSkip to search



Minimizing environmental footprint

Camurus strives to conduct a sustainable business where environmental and climate considerations are integrated into the company’s decisions. Together with suppliers and other stakeholders, the company works to minimize its operational and product-related impact throughout the entire value chain. This includes the development of circular solutions and avoiding incidents with impact on the environment.

Important aspects

Greenhouse Gas emissions and climate change

Camurus aims to reduce the company’s total climate footprint. The company’s greatest climate impact is found within scope 3, and in 2023 the company continue the work of mapping and reporting the emissions from scope 3 according to the Greenhouse Gas Protocol standard.  

Pharmaceuticals in the environment

Camurus develops long-acting medicines, which enables smaller total amount of active substance for the same effect and less travels to/from pharmacy or clinic. This can result in reduced environmental impact throughout the entire value chain, including lower emissions of active substances into nature.

Environmental impact

Camurus strives to minimize the environmental impact of its products as much as possible, both related to water consumption, waste, use of resources and chemicals, energy flows etc. 

Our goals by 2026

  • Reduce product manufacturing waste by 20%1) from 2023 to the end of 2026
  • Increase the use of packaging material originating from sustainable sources to at least 50%
  • Reduce Scope 12) and 23) emissions by 50% from 2023 to end of 2026
  • Reduce selected Scope 35,6) emissions by 20% from 2023 to end of 2026

Climate impact in the value chain

To reduce Camurus’ total climate footprint in its own operations, production, distribution and use of medicines, Camurus in 2022 began to map and measure its climate impact according to the Greenhouse Gas Protocol standard.4) For 2022, Camurus reported data for scope 12) and 23) and partly for scope 35)An environmental mapping of Camurus’ full value chain is ongoing.

Our achievements

  • 162.4t

    scope 1 emissions: company cars and use of fuel oil*

  • 8.9t

    scope 2 emissions: use of energy, heating, cooling*

  • 60.3t

    scope 3 emissions: fuel and energy related emissions not included in scope 1 and 2*

  • 85%

    share of renewable energy of total energy consumption*

*as at end December 2022, source: Annual Report 2022. All emissions are reported in CO2 equivalents (CO2e).

Minimizing pharmaceuticals in the nature

Since the bioavailability (the amount of the active substance that the body can assimilate) of Camurus’ currently long-acting marketed product is higher than in other products administered orally, the amount of active substance in Camurus’ product is five to six times lower than in its product predecessor.7 This means less active substance is needed for the same effect.

Additionally, a long-acting medicine with a smaller amount of active substance results in a reduced environmental impact throughout the entire value chain, leading to lower emissions of active substances into nature.

In-depth data

For more in-depth data on focus area planet see Camurus' Annual Report 2022


  1. Normalized to number of product units.
  2. Scope 1 emissions include direct emissions from owned or controlled sources.

  3. Scope 2 emissions include indirect emissions from the generation of purchased energy.

  4. The GHG Protocol is a globally standardized framework for measuring and managing greenhouse gas (GHG) emissions.

  5. Scope 3 emissions include all indirect emissions (excluding scope 2) that occur in the company's supply chain, both upstream and downstream.

  6. The goal includes purchased goods and services, upstream transportation and distribution, and business travel (ie category 1, 4 and 6 in GHG Protocol).

  7. Buvidal Prescribing Information: